A cash-generating pharmaceutical portfolio managing product-cycle pressure
Bristol Myers Squibb combines modest long-run revenue growth with recurring operating and free cash generation and relatively modest capital requirements. Reported earnings are more volatile than cash flow because acquisitions, amortization, impairments, pricing changes, and patent-driven generic erosion affect the income statement.